KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Shares Repurchased (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Shares Repurchased for 17 consecutive years, with $302.0 million as the latest value for Q4 2025.

  • Quarterly Shares Repurchased fell 4.13% to $302.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $893.0 million through Dec 2025, down 31.04% year-over-year, with the annual reading at $893.0 million for FY2025, 31.04% down from the prior year.
  • Shares Repurchased hit $302.0 million in Q4 2025 for Abbott Laboratories, down from $305.0 million in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $2.3 billion in Q1 2022 to a low of $2.0 million in Q3 2023.
  • Historically, Shares Repurchased has averaged $475.4 million across 5 years, with a median of $310.0 million in 2024.
  • Biggest five-year swings in Shares Repurchased: plummeted 99.75% in 2023 and later skyrocketed 37450.0% in 2024.
  • Year by year, Shares Repurchased stood at $974.0 million in 2021, then fell by 29.67% to $685.0 million in 2022, then crashed by 62.19% to $259.0 million in 2023, then grew by 21.62% to $315.0 million in 2024, then fell by 4.13% to $302.0 million in 2025.
  • Business Quant data shows Shares Repurchased for ABT at $302.0 million in Q4 2025, $305.0 million in Q3 2025, and $6.0 million in Q2 2025.